GLUEMonte Rosa Therapeutics, Inc.

$14.37

$4.1952 weeks$25.31

Price

$14.37+240%1Y

1M-38%1Y+240%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Average

5/10

Value41

Quality50

Momentum91

Growth6

Strongest Momentum, weakest Growth · ranked vs Healthcare peers. The five questions below judge the company on its own terms.

What they do

We are a clinical-stage biotechnology company developing a portfolio of novel and proprietary molecular glue degraders, or MGDs. MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins, in effect editing the human proteome. MGDs function by inducing the engagement of an E3 ligase, such as cereblon, with defined structural features on surfaces of target proteins.

In the company’s own words · 10-K filed Mar 17, 2026 · SEC EDGAR

P/E (TTM)-

Market Cap$1.55B

1Y Return+240%

5Y Return-44%

Monte Rosa Therapeutics, Inc. (GLUE) reported revenue of $9.0M in Q2 2026 (quarter ended June 30, 2026), down 61% from the same quarter a year earlier. That came with net loss of $43M. For the full year FY2025, revenue was $124M (+64% year on year) and net income −$39M.

Raw charts

9 series · TTM

As reported to the SEC, without any scoring.

Biotechnology

Ranks #111 of 145 by Smart Score

Compare peers

TYRA+1.9%

Tyra Biosciences, Inc.

RAPP-2.7%

Rapport Therapeutics, Inc.

MESO-6.8%

Mesoblast Limited

TSHA-11%

Taysha Gene Therapies, Inc.

IOVA-0.94%

Iovance Biotherapeutics, Inc.

RXRX+3.4%

Recursion Pharmaceuticals, Inc.